Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA). APPROACH AND RESU...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirschfield, Gideon M., Shiffman, Mitchell L., Gulamhusein, Aliya, Kowdley, Kris V., Vierling, John M., Levy, Cynthia, Kremer, Andreas E., Zigmond, Ehud, Andreone, Pietro, Gordon, Stuart C., Bowlus, Christopher L., Lawitz, Eric J., Aspinall, Richard J., Pratt, Daniel S., Raikhelson, Karina, Gonzalez-Huezo, Maria S., Heneghan, Michael A., Jeong, Sook-Hyang, Ladrón de Guevara, Alma L., Mayo, Marlyn J., Dalekos, George N., Drenth, Joost P.H., Janczewska, Ewa, Leggett, Barbara A., Nevens, Frederik, Vargas, Victor, Zuckerman, Eli, Corpechot, Christophe, Fassio, Eduardo, Hinrichsen, Holger, Invernizzi, Pietro, Trivedi, Palak J., Forman, Lisa, Jones, David E.J., Ryder, Stephen D., Swain, Mark G., Steinberg, Alexandra, Boudes, Pol F., Choi, Yun-Jung, McWherter, Charles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Immune-Mediated Diseases, DILI, and Biliary Tract Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344437/
https://www.ncbi.nlm.nih.gov/pubmed/37386786
http://dx.doi.org/10.1097/HEP.0000000000000395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344437/
https://www.ncbi.nlm.nih.gov/pubmed/37386786
http://dx.doi.org/10.1097/HEP.0000000000000395

Ejemplares similares